A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer
Nanobubble (NB), a newly developed nanoscaled ultrasound contrast agent (UCA) for molecular imaging, has been widely researched for these years. Targeting it with functional molecule, nanobubble can adhere selectively to cellular epitopes and receptors outside the vasculature via enhanced permeabili...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2018/6202876 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553464771641344 |
|---|---|
| author | Wei Lv Yamei Shen Hengli Yang Rui Yang Wenbin Cai Jian Zhang Lijun Yuan Yunyou Duan Li Zhang |
| author_facet | Wei Lv Yamei Shen Hengli Yang Rui Yang Wenbin Cai Jian Zhang Lijun Yuan Yunyou Duan Li Zhang |
| author_sort | Wei Lv |
| collection | DOAJ |
| description | Nanobubble (NB), a newly developed nanoscaled ultrasound contrast agent (UCA) for molecular imaging, has been widely researched for these years. Targeting it with functional molecule, nanobubble can adhere selectively to cellular epitopes and receptors outside the vasculature via enhanced permeability and retention (EPR) effect of tumor blood vessel. To enhance the targeting rate of our previous prepared NBs-Affibody for HER2 (+) breast cancer imaging, we introduced a near-infrared fluorescent (NIRF) dye, IR783, in this study to enhance tumor-specific targeting rate and provide a promising modality for dual-mode imaging. The prepared IR783-NBs-Affibody presented a uniform nanoscale size around 482.7 ± 54.3 nm, good biosecurity, and stability over time. The encapsulation efficiency (EE) of IR-783 was 15.09% in the conjugates leading to a successful NIR fluorescence and ultrasound enhancement imaging ex vivo. IR783-NBs-Affibody was able to automatically accumulate on BT474 cells with a highly increased targeting rate of 85.4% compared with previous NBs-Affibody of 26.6%, while Affibody-guided HER2 binding was only found in HER2-positive cell lines (BT474 and T-47D). The newly developed IR783-NBs-Affibody is characterized with favorable HER2 targeting ability and bimodal imaging capability for breast cancer. Thus, IR783-NBs-Affibody holds great potential in molecular diagnosis for patients with breast cancer. |
| format | Article |
| id | doaj-art-562278873f6d449e8ac4cdfd061d1814 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-562278873f6d449e8ac4cdfd061d18142025-02-03T05:53:56ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/62028766202876A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast CancerWei Lv0Yamei Shen1Hengli Yang2Rui Yang3Wenbin Cai4Jian Zhang5Lijun Yuan6Yunyou Duan7Li Zhang8Department of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaState Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, ChinaNanobubble (NB), a newly developed nanoscaled ultrasound contrast agent (UCA) for molecular imaging, has been widely researched for these years. Targeting it with functional molecule, nanobubble can adhere selectively to cellular epitopes and receptors outside the vasculature via enhanced permeability and retention (EPR) effect of tumor blood vessel. To enhance the targeting rate of our previous prepared NBs-Affibody for HER2 (+) breast cancer imaging, we introduced a near-infrared fluorescent (NIRF) dye, IR783, in this study to enhance tumor-specific targeting rate and provide a promising modality for dual-mode imaging. The prepared IR783-NBs-Affibody presented a uniform nanoscale size around 482.7 ± 54.3 nm, good biosecurity, and stability over time. The encapsulation efficiency (EE) of IR-783 was 15.09% in the conjugates leading to a successful NIR fluorescence and ultrasound enhancement imaging ex vivo. IR783-NBs-Affibody was able to automatically accumulate on BT474 cells with a highly increased targeting rate of 85.4% compared with previous NBs-Affibody of 26.6%, while Affibody-guided HER2 binding was only found in HER2-positive cell lines (BT474 and T-47D). The newly developed IR783-NBs-Affibody is characterized with favorable HER2 targeting ability and bimodal imaging capability for breast cancer. Thus, IR783-NBs-Affibody holds great potential in molecular diagnosis for patients with breast cancer.http://dx.doi.org/10.1155/2018/6202876 |
| spellingShingle | Wei Lv Yamei Shen Hengli Yang Rui Yang Wenbin Cai Jian Zhang Lijun Yuan Yunyou Duan Li Zhang A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer Journal of Immunology Research |
| title | A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer |
| title_full | A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer |
| title_fullStr | A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer |
| title_full_unstemmed | A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer |
| title_short | A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer |
| title_sort | novel bimodal imaging agent targeting her2 molecule of breast cancer |
| url | http://dx.doi.org/10.1155/2018/6202876 |
| work_keys_str_mv | AT weilv anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT yameishen anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT hengliyang anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT ruiyang anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT wenbincai anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT jianzhang anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT lijunyuan anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT yunyouduan anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT lizhang anovelbimodalimagingagenttargetingher2moleculeofbreastcancer AT weilv novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT yameishen novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT hengliyang novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT ruiyang novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT wenbincai novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT jianzhang novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT lijunyuan novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT yunyouduan novelbimodalimagingagenttargetingher2moleculeofbreastcancer AT lizhang novelbimodalimagingagenttargetingher2moleculeofbreastcancer |